Natixis Advisors LLC Buys 270,476 Shares of The Cooper Companies, Inc. $COO

Natixis Advisors LLC raised its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 820.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 303,456 shares of the medical device company’s stock after acquiring an additional 270,476 shares during the quarter. Natixis Advisors LLC’s holdings in Cooper Companies were worth $24,871,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Root Financial Partners LLC lifted its holdings in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares during the period. Bell Investment Advisors Inc increased its stake in shares of Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after buying an additional 219 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in shares of Cooper Companies in the second quarter valued at $36,000. True Wealth Design LLC increased its stake in shares of Cooper Companies by 484.8% in the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares in the last quarter. Finally, Cromwell Holdings LLC increased its stake in shares of Cooper Companies by 128.8% in the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock valued at $40,000 after buying an additional 273 shares in the last quarter. 24.39% of the stock is owned by institutional investors.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies reported fiscal second-quarter EPS of $1.21, beating the $1.10 consensus, while revenue of $1.08 billion also topped estimates and rose 7.9% year over year. Cooper Companies earnings transcript
• Positive Sentiment: The company also reaffirmed growth momentum by posting improved profitability, with net margin of 9.67% and return on equity of 10.34%, which should support investor confidence. Cooper Companies press release
• Neutral Sentiment: Management guided fiscal 2026 EPS to $4.58-$4.66, which is close to the analyst view of $4.62 and suggests the outlook was acceptable, but not a major upside surprise. Cooper Companies stock page
• Neutral Sentiment: Several earnings-preview articles published ahead of the report likely added attention, but the main stock driver today appears to be the actual results and guidance. Yahoo Finance preview

Cooper Companies Price Performance

Shares of COO stock opened at $62.02 on Friday. The stock has a 50-day moving average price of $65.17 and a 200 day moving average price of $74.57. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The firm has a market cap of $12.10 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 1.56 and a beta of 0.87. The Cooper Companies, Inc. has a 12 month low of $58.89 and a 12 month high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. Cooper Companies had a return on equity of 10.34% and a net margin of 9.67%.The company’s revenue was up 7.9% on a year-over-year basis. During the same period last year, the company earned $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Research analysts expect that The Cooper Companies, Inc. will post 4.62 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on COO. Piper Sandler set a $86.00 target price on Cooper Companies and gave the company an “overweight” rating in a research note on Monday. Barclays raised their target price on Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, March 6th. Citigroup restated a “neutral” rating and issued a $69.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. Mizuho set a $85.00 target price on Cooper Companies and gave the company an “outperform” rating in a research note on Thursday. Finally, Rothschild & Co Redburn lowered Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price for the company. in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.00.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.